# OnCo record ateganosine (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ateganosine/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ateganosine" ;
  schema:name "Ateganosine (THIO)"@en ;
  schema:alternateName "THIO"@en, "6-thio-dG"@en, "6-thio-2'-deoxyguanosine"@en, "beta-thioguanine deoxyriboside"@en ;
  schema:description "Ateganosine (THIO) is an experimental drug from MAIA Biotechnology that is built into the ends of chromosomes by telomerase, an enzyme most cancers switch on, and damages them. It is being tested before the immunotherapy cemiplimab in advanced non-small cell lung cancer."@en ;
  schema:url <https://onco.cc/drugs/ateganosine/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://maiabiotech.com/pipeline/thio/>, <https://doi.org/10.1158/2159-8290.CD-14-0609>, <https://doi.org/10.1016/j.ccell.2020.05.020>, <https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1350>, <https://clinicaltrials.gov/study/NCT05208944>, <https://clinicaltrials.gov/study/NCT06908304> ;
  onco:status "phase-3" ;
  onco:modality "small molecule (nucleoside analogue)" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/tert/> ;
  onco:drugs <https://onco.cc/drugs/cemiplimab/> ;
  onco:companies <https://onco.cc/companies/maia-biotechnology/> ;
  onco:pathways <https://onco.cc/pathways/telomere-maintenance/> ;
  onco:trials <https://onco.cc/trials/nct05208944/>, <https://onco.cc/trials/nct06908304/> .